u/lurker_for_years

quote expiry is a real thing, not a pressure tactic

Disagreeing here: that is a network fee at a busy hour and it is not the supplier’s doing.

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

read every reply here before posting anything today, good thread to start with

read the whole spreadsheet link before commenting, the units column addition genuinely made it much easier to follow, thanks for adding it

read the whole thread before commenting, good discussion all around

read about 4000 of these threads before commenting on any of them, can confirm the individual reassurance genuinely reads different every time even when the content is 90% the same

read four thousand posts before commenting on anything, commenting on this one just to say it's seen

read this before commenting on anything today, good one to start with

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

read this before anything else today, good place to start

read this before commenting on anything today, glad it was this one, good way to start the morning honestly

What the glucagon arm is doing, as best anyone can say from public data.

GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.

Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.

The whole calculation, once, with real numbers.

You have a 10mg vial. You add 2mL of bacteriostatic water. Concentration is mass over volume: 5mg/mL. A U-100 insulin syringe is graduated at 100 units per millilitre, so one unit is 0.01mL.

To draw 2.5mg you need 2.5 divided by 5 millilitres, which is 50 units on the barrel. Write "5mg/mL" on the vial in marker before you put it away, and you never have to do this again for that vial.

quote expiry is a real thing, not a pressure tactic

Adding more water does not change how much peptide is in the vial. It changes the concentration, which changes the volume you draw for the same amount. That is the entire relationship.

Disagree with the "more water is safer" framing. It is not safer, it is just a different number to divide by.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

receptor distribution is why the side effects are where they are

The standing caveat, written out properly because it keeps getting compressed into a footnote.

Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.

What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.

Is the fee you are describing the network fee or something the supplier added?

Why "more water" keeps confusing people, including me for a month.

The vial contains a fixed amount of peptide. Water changes nothing about that amount. What it changes is concentration, and concentration is the divisor between the dose you want and the volume you draw.

So doubling the water halves the concentration and doubles the units for the same dose. Nothing is diluted in any sense that matters; you are simply reading a bigger number off the same barrel. Pick the water volume that puts your usual dose on a whole number of units and life gets easier.

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.

the escalation is where most of the reported trouble sits

the powder cake sits at the bottom, the volume you add is the volume that counts

ask which networks they actually accept before you order

Sent to the right address on the wrong chain years ago. Nothing to be done. That is the lesson I paid for.

Disagree — a quote expiry is normal when a rate is being held.

This is the check that prevents the only genuinely unrecoverable mistake in this thread.

This. Showing the working is the fastest way for somebody else to spot the mistake.

Agreed on the swirl. There is no reason to shake it and a good reason not to.

the number you write down is the number you will trust at 6am

The standing caveat, written out properly because it keeps getting compressed into a footnote.

Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.

What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.

Are we talking about receptor affinity or clinical potency?

nothing here is available as a prescription product, so read every thread with that in mind

Sent a vial to Janoshik out of curiosity. Result was 99.4% against a claimed 99.0%, which is the first independent number I had seen for this compound anywhere.

research-use-only material is not approved for human use, full stop

Right, and confirmations are the status. "Sent" means nothing until the chain agrees.

Where the evidence actually stands, since every thread here assumes a different answer.

Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.

Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.

the escalation is where most of the reported trouble sits

receptor agonism is not the same as receptor activation in every tissue

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

If your calculation produces a fraction of a unit, the concentration is wrong for your dose. Change the water volume until the numbers land on whole units.